Odyssey Health Stock

Odyssey Health, Inc. focuses on acquiring and developing medical products. The company is developing technologies that have a technological advantage, superior clinical utility, and a substantial market opportunity within significant target markets across the globe.

The company’s business model is to develop or acquire unique medical-related products, engage third parties to assist in the development and manufacturing of such products, and then distribute the products through various distribution channels, including third parties. The company owns potentially life-saving technologies: the CardioMap heart monitoring and screening device; the Save A Life choking rescue device; and ONP-002 which is a unique neurosteroid drug compound intended to treat mild traumatic brain injuries also known as concussions. The company owns fifty percent of another unique neuro-steroid, ONP-001, intended to treat rare brain disorders.

The company intends to license, improve and/or develop its products and identify and select distribution channels. The company plans to establish agreements with distributors to get products to market quickly, as well as to undertake and engage in its own direct marketing efforts.

The company intends to engage third party research and development firms who specialize in the creation of medical products to assist it in the development. The company will apply for trademarks and patents as it develops proprietary products.

The CardioMap System is intended to be a heart monitoring and screening device based on a novel method of Dispersion Mapping in ECG analysis for the early, non-invasive testing for coronary heart disease (CHD). The company has exclusive, royalty free rights to USPTO patent number 7,519,416 B2 related to the CardioMap technology.

In 2019, the company purchased all intellectual property, including two patents for the choking rescue device: patent Number RE45, 535 E, and patent Number 8,454,624 B2. The Save a Life (SAL) choking rescue device is in development and is designed to be a safe, and easy-to-use device for removing a lodged mass from the throat of a choking victim. The device includes a pump for creating a vacuum chamber, which is connected seamlessly with a replaceable/disposable mouthpiece.

The neurosteroid, ONP-001, is intended to improve function and lifespan in pediatric disorders where Central Nervous System (CNS) de-myelination and cell death is widespread in the cortex, subcortical nuclei, brainstem, and cerebellar regions. ONP-001, a new chemical entity, is designed to work through gene amplification to simultaneously remove intra-neuronal debris while promoting antioxidant capacity and myelin repair/cell proliferation. To market the ONP-001 neurosteroid, further development and clinical studies are required. ONP-001 will also require approval by the FDA to be sold in the United States.

The company owns one hundred percent (100%) of the drug compound PRV-002. The company has changed the name of the drug to ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). Results of preclinical studies suggest that ONP-002 has an equivalent, and potentially superior, neuroprotective effect compared to related neurosteroids. In animal models of mild brain injury ONP-002 reduced the behavioral pathology associated with brain injury symptoms such as short-term memory loss, depression/anxiety-like behavior, and motor-sensory impairment. The drug is administered through the nasal passage from a novel device. ONP-002 is lipophilic and can cross the blood-brain barrier, thus supporting its potential to rapidly eliminate swelling, oxidative stress, and inflammation in the brain while restoring proper blood flow through gene amplification.

Strategy

The key elements of the company’s strategy are to distribute or license agreements; identify and develop its products for additional proprietary uses; intend to pursue the development and acquisition of other product candidates and market any new products, if cleared or approved; and seek partners to assist in the further development of its drug device combination products. The company has development programs for devices and pharmaceutical drugs, which are in various stages of development.

Governmental Regulation

The processing, formulation, safety, manufacturing, packaging, labeling, advertising and distribution of the company’s products may be subject to certain regulations by one or more federal agencies, including the FDA, Housing and Human Services (the HHS), the Federal Trade Commission (the FTC), the Consumer Product Safety Commission (the CPSC), the United States Department of Agriculture (the USDA) and the Environmental Protection Agency (the EPA), and by various agencies of the states and localities in which its products are sold. To sell, market and distribute the CardioMap, the Save a Life or the drug compound products, clearance or approval from the FDA is required.

History

The company was founded as a Nevada corporation in 2014. The company was incorporated in 2014. It was formerly known as Odyssey Group International, Inc. and changed its name to Odyssey Health, Inc. in 2021.